文档介绍：低分子肝素钙治疗过敏性紫癜的效果
作者:李晶叶倩刘华林孙清
【摘要】目的探讨低分子肝素钙治疗儿童过敏性紫癜(HSP)及预防过敏性紫癜肾炎(HSPN)的临床效果。方法将60例首次发作HSP病儿,随机分为低分子肝素钙治疗组30例和常规治疗组30例,常规治疗组应用维生素C、川芎嗪、钙剂、西咪替丁治疗,低分子肝素钙治疗组在此基础上加用低分子肝素钙皮下注射,观察并比较两组疗效、皮疹消退时间和随诊过程(3个月)中肾炎的发生率。结果低分子肝素钙治疗组的皮疹消退时间明显短于常规治疗组(t=,P<),HSPN的发生率也明显低于常规治疗组(χ2=,P<)。结论低分子肝素钙皮下注射治疗HSP、预防HSPN疗效显著,且安全、可靠,无明显不良反应。
【关键词】肝素钙低分子量紫癜过敏性治疗结果儿童
[ABSTRACT] Objective To evaluate the effectiveness of lowmolecularheparin calcium (LMHC) in the treatment of HenochSchonleinpurpura (HSP) and prevention of HenochSchonleinpurpura nephritis (HSPN). Methods Sixty patients with HSP were evenly divided into LMHC treatment group and routine treatment routine group, vitamin C, ligustrazine, calcium and cimetidine were administered;for LMHC group, LMHC was hypodermic injection besides the drugs used in the routine efficacy, deflorescence time and incidence of nephritis were observed in both groups. Results The deflorescen
ce time was shorter (t=,P<), the incidence of nephritis was lower (χ2=,P<) in LMHC group than routine Lowmoleculrheparin calcium is effective and safe for the treatment of HSP and prevention of HSPN.
[KEY WORDS] Heparin calcium, low molecular weight; Purpura, HenochSchoenlein; Treatment e; Children
过敏性紫癜(HSP)是一种弥漫性血管炎症,是儿科最常见的结缔组织病,多见于2~8岁儿童。近年来其发病率增高。目前,其发病机制尚不十分明确,临床缺乏特异性治疗药物